JP2021522269A5 - - Google Patents
Info
- Publication number
- JP2021522269A5 JP2021522269A5 JP2020560257A JP2020560257A JP2021522269A5 JP 2021522269 A5 JP2021522269 A5 JP 2021522269A5 JP 2020560257 A JP2020560257 A JP 2020560257A JP 2020560257 A JP2020560257 A JP 2020560257A JP 2021522269 A5 JP2021522269 A5 JP 2021522269A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- integrin
- group
- cargo molecule
- targeting
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024232254A JP2025060958A (ja) | 2018-04-27 | 2024-12-27 | インテグリン標的化リガンドとその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663763P | 2018-04-27 | 2018-04-27 | |
| US62/663,763 | 2018-04-27 | ||
| US201962790372P | 2019-01-09 | 2019-01-09 | |
| US62/790,372 | 2019-01-09 | ||
| PCT/US2019/029393 WO2019210200A1 (en) | 2018-04-27 | 2019-04-26 | Integrin targeting ligands and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024232254A Division JP2025060958A (ja) | 2018-04-27 | 2024-12-27 | インテグリン標的化リガンドとその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021522269A JP2021522269A (ja) | 2021-08-30 |
| JP2021522269A5 true JP2021522269A5 (https=) | 2022-06-14 |
| JPWO2019210200A5 JPWO2019210200A5 (https=) | 2022-06-14 |
| JP7704529B2 JP7704529B2 (ja) | 2025-07-08 |
Family
ID=68294255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560257A Active JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
| JP2024232254A Pending JP2025060958A (ja) | 2018-04-27 | 2024-12-27 | インテグリン標的化リガンドとその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024232254A Pending JP2025060958A (ja) | 2018-04-27 | 2024-12-27 | インテグリン標的化リガンドとその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210093725A1 (https=) |
| EP (2) | EP4435000A3 (https=) |
| JP (2) | JP7704529B2 (https=) |
| KR (1) | KR102787533B1 (https=) |
| CN (2) | CN118994152A (https=) |
| AU (1) | AU2019260738B2 (https=) |
| BR (1) | BR112020021949A2 (https=) |
| CA (1) | CA3097656A1 (https=) |
| DK (1) | DK3784269T3 (https=) |
| ES (1) | ES2983950T3 (https=) |
| FI (1) | FI3784269T3 (https=) |
| HR (1) | HRP20240907T1 (https=) |
| IL (2) | IL309955A (https=) |
| JO (1) | JOP20200266A1 (https=) |
| MX (1) | MX2020011290A (https=) |
| SA (1) | SA520420426B1 (https=) |
| SG (1) | SG11202009734VA (https=) |
| SI (1) | SI3784269T1 (https=) |
| TW (1) | TW202014206A (https=) |
| WO (1) | WO2019210200A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210093725A1 (en) * | 2018-04-27 | 2021-04-01 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
| SG11202105577TA (en) | 2019-01-09 | 2021-06-29 | Arrowhead Pharmaceuticals Inc | Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use |
| IL301187A (en) * | 2020-09-11 | 2023-05-01 | Arrowhead Pharmaceuticals Inc | RNAi agents for suppressing DUX4 expression, preparations containing them and uses thereof |
| EP4367246A2 (en) * | 2021-07-07 | 2024-05-15 | Alnylam Pharmaceuticals, Inc. | Integrin targeting ligands for ocular delivery of rnai compounds |
| CN121399119A (zh) * | 2023-06-19 | 2026-01-23 | 广东众生睿创生物科技有限公司 | 一种整合素配体及其用途 |
| WO2025252118A1 (zh) * | 2024-06-06 | 2025-12-11 | 苏州瑞博生物技术股份有限公司 | 整联蛋白αvβ6特异性配体化合物、缀合物、药物组合物及其用途 |
| WO2025261536A1 (zh) * | 2024-06-21 | 2025-12-26 | 长春金赛药业有限责任公司 | 一种整联蛋白配体关键中间体及其制备方法 |
| WO2026034639A1 (ja) * | 2024-08-09 | 2026-02-12 | 株式会社Spin Wave | ペプチド合成用可溶性担体およびこれを用いた合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ES2241192T3 (es) * | 1997-12-17 | 2005-10-16 | MERCK & CO., INC. (A NEW JERSEY CORP.) | Antagonistas del receptor de integrina. |
| US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| CN102026671B (zh) * | 2008-03-14 | 2014-09-03 | Visen医药公司 | 整联蛋白靶向试剂及使用其的体内和体外成像方法 |
| BR112014016736A8 (pt) * | 2012-01-27 | 2017-07-04 | Hoffmann La Roche | composto, composição farmacêutica, método para tratamento, uso de um composto e invenção |
| CA2895430C (en) | 2013-01-28 | 2021-11-23 | Janssen Sciences Ireland Uc | Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents |
| SG10201706960TA (en) * | 2013-02-28 | 2017-10-30 | Arrowhead Res Corp | Organic compositions to treat epas1-related diseases |
| WO2015021092A1 (en) | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
| KR102647026B1 (ko) * | 2015-02-19 | 2024-03-12 | 사이플루어 라이프 사이언시즈, 인크 | 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 |
| US11971402B2 (en) * | 2015-04-24 | 2024-04-30 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
| KR20170141757A (ko) * | 2015-04-30 | 2017-12-26 | 사이플루어 라이프 사이언시즈, 인크 | 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도 |
| HK1252852A1 (zh) | 2015-05-29 | 2019-06-06 | Arrowhead Pharmaceuticals, Inc. | 阻止HIF2α基因表达的组合物及方法 |
| US20210093725A1 (en) * | 2018-04-27 | 2021-04-01 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
-
2019
- 2019-04-26 US US17/050,042 patent/US20210093725A1/en active Pending
- 2019-04-26 EP EP24179088.0A patent/EP4435000A3/en active Pending
- 2019-04-26 BR BR112020021949-5A patent/BR112020021949A2/pt unknown
- 2019-04-26 ES ES19794009T patent/ES2983950T3/es active Active
- 2019-04-26 KR KR1020207033772A patent/KR102787533B1/ko active Active
- 2019-04-26 IL IL309955A patent/IL309955A/en unknown
- 2019-04-26 CN CN202411099363.5A patent/CN118994152A/zh active Pending
- 2019-04-26 EP EP19794009.1A patent/EP3784269B1/en active Active
- 2019-04-26 CA CA3097656A patent/CA3097656A1/en active Pending
- 2019-04-26 SI SI201930780T patent/SI3784269T1/sl unknown
- 2019-04-26 SG SG11202009734VA patent/SG11202009734VA/en unknown
- 2019-04-26 MX MX2020011290A patent/MX2020011290A/es unknown
- 2019-04-26 JO JOP/2020/0266A patent/JOP20200266A1/ar unknown
- 2019-04-26 AU AU2019260738A patent/AU2019260738B2/en active Active
- 2019-04-26 WO PCT/US2019/029393 patent/WO2019210200A1/en not_active Ceased
- 2019-04-26 FI FIEP19794009.1T patent/FI3784269T3/fi active
- 2019-04-26 JP JP2020560257A patent/JP7704529B2/ja active Active
- 2019-04-26 IL IL278304A patent/IL278304B2/en unknown
- 2019-04-26 DK DK19794009.1T patent/DK3784269T3/da active
- 2019-04-26 CN CN201980028704.0A patent/CN112074290B/zh active Active
- 2019-04-26 HR HRP20240907TT patent/HRP20240907T1/hr unknown
- 2019-04-29 TW TW108114935A patent/TW202014206A/zh unknown
-
2020
- 2020-10-27 SA SA520420426A patent/SA520420426B1/ar unknown
-
2024
- 2024-12-27 JP JP2024232254A patent/JP2025060958A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522269A5 (https=) | ||
| JP6932389B2 (ja) | 標的化コンジュゲートならびにその粒子及び製剤 | |
| JP5960890B2 (ja) | 担体ナノ粒子ならびに関連する組成物、方法およびシステム | |
| JP2021050212A (ja) | 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム | |
| JP2023541427A (ja) | 骨格筋送達プラットフォーム及び使用方法 | |
| US20160193354A1 (en) | Antisense oligonucleotides with improved pharmacokinetic properties | |
| Fuentes-Paniagua et al. | Thiol-ene synthesis of cationic carbosilane dendrons: a new family of synthons | |
| EA014097B1 (ru) | ОЛИГОНУКЛЕОТИДЫ ЗАМКНУТОЙ НУКЛЕИНОВОЙ КИСЛОТЫ (LNA) ДЛЯ МОДУЛИРОВАНИЯ ЭКСПРЕССИИ HIF-1a И ИХ ПРИМЕНЕНИЕ | |
| KR20150100706A (ko) | 입자 내에 캡슐화된 표적화된 콘쥬게이트 및 이의 제형 | |
| UA125655C2 (uk) | Терапевтичні дендримери | |
| JP2011514423A (ja) | 生分解性架橋分枝状ポリ（アルキレンイミン） | |
| CN105007905A (zh) | 靶向纳米粒子 | |
| CN116348150A (zh) | 用于递送治疗剂的脂质缀合物 | |
| JP6316209B2 (ja) | αＶβ３を発現する細胞への標的化送達のためのインテグリンアンタゴニスト結合体 | |
| US20240050463A1 (en) | Therapeutic compositions and methods for treating hepatitis b | |
| JPWO2019210200A5 (https=) | ||
| DK2806897T3 (en) | INTEGRIN ANAGONIST CONJUGATES FOR TARGETED RELEASE TO LFA-1 EXPRESSING CELLS | |
| US20130011448A1 (en) | System for improved delivery of gene modulating compounds | |
| US20130079383A1 (en) | Lipid Compounds Targeting VLA-4 | |
| JP2001515060A (ja) | 新リポポリアミン、その調製および適用 | |
| MX2014008403A (es) | Conjugados de antagonista de la integrina para su suministro dirigido a celulas que expresan vla-4. | |
| US20200046846A1 (en) | Modified oligonucleotides and therapeutic uses thereof | |
| US9447035B2 (en) | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 | |
| Panda et al. | Targeted leukemia therapy with solid–lipid nanoparticles: Potential and progress | |
| HK1202426B (en) | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3 |